Free Trial
→ New Chip takes minutes, not days (From Eagle Publishing) (Ad)tc pixel Free XRTX Stock Alerts

XORTX Therapeutics (XRTX) Competitors

XORTX Therapeutics logo
$1.41 -0.44 (-23.78%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.05 (+3.19%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

XRTX vs. FNCH, KPRX, CALC, INTS, and SCNX

Should you buy XORTX Therapeutics stock or one of its competitors? XORTX Therapeutics's main competitors and comparable companies include Finch Therapeutics Group (FNCH), Kiora Pharmaceuticals (KPRX), CalciMedica (CALC), Intensity Therapeutics (INTS), and Scienture (SCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does XORTX Therapeutics compare to Finch Therapeutics Group?

XORTX Therapeutics (NASDAQ:XRTX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

XORTX Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -137.85% -108.16%
Finch Therapeutics Group N/A -69.14%-26.92%

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, XORTX Therapeutics had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for XORTX Therapeutics and 0 mentions for Finch Therapeutics Group. XORTX Therapeutics' average media sentiment score of 0.90 beat Finch Therapeutics Group's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
XORTX Therapeutics Positive
Finch Therapeutics Group Neutral

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

Summary

XORTX Therapeutics beats Finch Therapeutics Group on 6 of the 11 factors compared between the two stocks.

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

XORTX Therapeutics (NASDAQ:XRTX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

XORTX Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Kiora Pharmaceuticals' return on equity of -63.38% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -137.85% -108.16%
Kiora Pharmaceuticals N/A -63.38%-44.33%

In the previous week, XORTX Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 4 mentions for XORTX Therapeutics and 3 mentions for Kiora Pharmaceuticals. XORTX Therapeutics' average media sentiment score of 0.90 beat Kiora Pharmaceuticals' score of 0.37 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XORTX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kiora Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A
Kiora PharmaceuticalsN/AN/A-$10.84M-$2.51N/A

Summary

XORTX Therapeutics beats Kiora Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does XORTX Therapeutics compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

CalciMedica has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$29.56M-$6.80N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A

CalciMedica's return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A N/A -155.24%
XORTX Therapeutics N/A -137.85%-108.16%

0.2% of XORTX Therapeutics shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CalciMedica presently has a consensus target price of $50.00, suggesting a potential upside of 3,837.01%. Given CalciMedica's stronger consensus rating and higher probable upside, equities research analysts clearly believe CalciMedica is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, XORTX Therapeutics had 1 more articles in the media than CalciMedica. MarketBeat recorded 4 mentions for XORTX Therapeutics and 3 mentions for CalciMedica. XORTX Therapeutics' average media sentiment score of 0.90 beat CalciMedica's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
XORTX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

XORTX Therapeutics beats CalciMedica on 7 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Intensity Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intensity Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 92.84%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Intensity Therapeutics is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, XORTX Therapeutics had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 4 mentions for XORTX Therapeutics and 2 mentions for Intensity Therapeutics. XORTX Therapeutics' average media sentiment score of 0.90 beat Intensity Therapeutics' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intensity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
XORTX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Intensity Therapeutics is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A

Intensity Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Intensity Therapeutics' return on equity of -116.61% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intensity TherapeuticsN/A -116.61% -94.01%
XORTX Therapeutics N/A -137.85%-108.16%

Summary

Intensity Therapeutics beats XORTX Therapeutics on 9 of the 14 factors compared between the two stocks.

How does XORTX Therapeutics compare to Scienture?

XORTX Therapeutics (NASDAQ:XRTX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 19.5% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Scienture had 5 more articles in the media than XORTX Therapeutics. MarketBeat recorded 9 mentions for Scienture and 4 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.90 beat Scienture's score of 0.50 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XORTX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Scienture
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Scienture has a consensus target price of $37.50, indicating a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scienture
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Scienture's return on equity of -53.51% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -137.85% -108.16%
Scienture N/A -53.51%-42.47%

XORTX Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Scienture has a beta of 3.34, meaning that its share price is 234% more volatile than the broader market.

XORTX Therapeutics has higher earnings, but lower revenue than Scienture. Scienture is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A
Scienture$430K14.34-$41.51M-$2.10N/A

Summary

Scienture beats XORTX Therapeutics on 12 of the 14 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XRTX vs. The Competition

Export
MetricXORTX TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.36M$12.29B$7.16B$13.21B
Dividend YieldN/A2.64%2.53%16.37%
P/E Ratio-0.52797.58275.3026.16
Price / SalesN/A939.75635.97107.53
Price / CashN/A85.9776.3853.09
Price / Book0.9410.7111.226.33
Net Income-$2.66M$2.84B$3.50B$382.15M
7 Day Performance-17.75%-0.94%-0.89%-1.40%
1 Month Performance-33.18%-4.89%-4.42%-3.47%
1 Year Performance-68.88%-4.12%7.03%1.18%

XORTX Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XRTX
XORTX Therapeutics
1.3496 of 5 stars		$1.41
-23.8%		N/A-68.4%$3.36MN/AN/AN/A
FNCH
Finch Therapeutics Group
N/A$7.30
flat		N/AN/A$11.72MN/AN/A190
KPRX
Kiora Pharmaceuticals
1.2885 of 5 stars		$2.58
+0.8%		N/A-9.9%$11.33M$16.02MN/A13
CALC
CalciMedica
3.5487 of 5 stars		$1.65
+1.9%		$50.00
+2,930.3%		-92.5%$11.06MN/AN/A15
INTS
Intensity Therapeutics
3.1698 of 5 stars		$3.21
-4.7%		$7.00
+118.1%		-54.1%$11MN/AN/A2,021

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel